17,261 trials
Pancreatic Cancer
Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients
Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection
Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c to Week 12 — -0.42; -0.52; -0.92; -0.80 % change
Male Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Maximum Tolerated Dose Determined by Dose-limiting Toxicities — 0; 0 Patients experiencing DLT
Head or Neck Cancer
Primary: Overall Response Rate — 2; 5 Participants
Precancerous Condition · Stage 0 Melanoma · Stage I Melanoma
Primary: Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation — 0.50; -0.12 score
Schizophrenia
Primary: Composite MATRICS Consensus Cognitive Battery Score — 27.9; 31.3; 32.5 composite score — p=0.21
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Relapse at 2 Years Post-transplant. — 6; 4 participants
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Stage I Mantle Cell Lymphoma
Primary: Complete Response (CR) Rate — 0.68 proportion
Severe Sepsis or Septic Shock
Primary: Plasma Cathelicidin (hCAP18) Protein Levels at 48 Hours — 76; 82 ng/ml — p=0.25
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST) — 3 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Response Rate — 34; 12.5 percentage of responding patients
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48 — -2.4; -2.2; -2.4; -2.2 units on a scale
Substance Use Disorders · Alcohol Abuse · Alcoholism
Primary: Abstinence Rate (During the Preceding 90 Days) at 12 Months Follow-up Point as Assessed by the Form-90 — 40; 38; 47; 51 participants